This is not just data analysis; it is a closed logical loop. The system can independently analyze a patient's genetic profile and prescribe drugs, eliminating the risks of incompatibility or side effects. Publication in a reputable scientific journal legitimizes the trend set by yesterday's contract between Novo Nordisk and OpenAI. AI agents (Agentic AI) are moving from the status of experimental prototypes to validated B2B solutions ready for implementation in actual clinical practice.
Source: Nature / npj Digital Medicine
ScienceNatureAgentic AIPharmacogenomicsB2B